ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

Lung Cancer

Volumn 50, Issue 2, 2005, Pages 211-219

  Wachters, F M ^a   Wong, L S M ^b   Timens, W ^a   Kampinga, H H ^b   Groen, H J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

BRCA1; Chemotherapy; ERCC1; Gemcitabine; Homologous recombination; hRad51; Non small cell lung cancer; Nucleotide excision repair

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAD51 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZATION; STAINING; SURVIVAL TIME; TUMOR BIOPSY;

ADULT; AGED; BIOPSY; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RAD51 RECOMBINASE; SURVIVAL ANALYSIS;

EID: 26444598043     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.06.013     Document Type: Article

References (39)

1. M.D. Brundage, D. Davies, and W.J. Mackillop Prognostic factors in non-small cell lung cancer: a decade of progress Chest 122 2002 1037 1057
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
3. H. Anderson, B. Lund, F. Bach, N. Thatcher, J. Walling, and H.H. Hansen Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study J Clin Oncol 12 1994 1821 1826
4. U. Gatzemeier, F.A. Shepherd, T. Le Chevalier, P. Weynants, B. Cottier, and H.J.M. Groen Activity of gemcitabine in patients with non-small-cell lung cancer: a multicentre, extended phase II study Eur J Cancer 32A 1996 243 248
5. M. Halme, A. Jekunen, K. Tamminen, and K. Mattson Phase II study of weekly gemcitabine in advanced non-small cell lung cancer Respir Med 91 1997 423 426
6. R.P. Perng, Y.M. Chen, J. Ming-Liu, C.M. Tsai, W.C. Lin, and K.Y. Yang Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study J Clin Oncol 15 1997 2097 2102
7. M. Takada, S. Negoro, S. Kudo, K. Furuse, H. Nishikawa, and Y. Takada Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study Cancer Chemother Pharmacol 41 1998 217 222
8. W.W. Ten Bokkel Huinink, B. Bergman, A. Chemaissani, W. Dornoff, P. Drings, and P.L. Kellokumpu-Lehtinen Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer Lung Cancer 26 1999 85 94
9. A. Yokoyama, Y. Nakai, S. Yoneda, Y. Kurita, and H. Niitani Activity of gemcitabine in the treatment of patients with non-small-cell lung cancer: a multicenter phase II study Anticancer Drugs 8 1997 574 581
10. P. Zatloukal, E. Kanitz, P. Magyar, J. Jassem, M. Krzakowski, and M. Pawlicki Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study Lung Cancer 22 1998 243 250
11. A.M. Bergman, V. Ruiz van Haperen, G. Veerman, C.M. Kuiper, and G.J. Peters Synergistic interaction between cisplatin and gemcitabine in vitro Clin Cancer Res 2 1996 521 530
12. C.J. van Moorsel, H.M. Pinedo, G. Veerman, A.M. Bergman, C.M. Kuiper, and J.B. Vermorken Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Br J Cancer 80 1999 981 990
13. M.A. Moufarij, D.R. Phillips, and C. Cullinane Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines Mol Pharmacol 63 2003 862 869
14. J.H. Hoeijmakers Genome maintenance mechanisms for preventing cancer Nature 411 2001 366 374
15. I.U. De Silva, P.J. McHugh, P.H. Clingen, and J.A. Hartley Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells Mol Cell Biol 20 2000 7980 7990
16. R.V. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, and M. Domine Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2002 2286 2291
17. C.H. Bosken, Q. Wei, C.I. Amos, and M.R. Spitz An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer J Natl Cancer Inst 94 2002 1091 1099
18. M. Crul, R.C. Van Waardenburg, S. Bocxe, M.A. Van Eijndhoven, D. Pluim, and J.H. Beijnen DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin Biochem Pharmacol 65 2003 275 282
19. F.M. Wachters, J.W.G. Van Putten, J.G. Maring, M.Z. Zdzienicka, H.J.M. Groen, and H.H. Kampinga Selective targeting of homologous DNA recombination repair by gemcitabine Int J Radiat Oncol Biol Phys 57 2003 553 562
20. E. Raderschall, K. Stout, S. Freier, V. Suckow, S. Schweiger, and T. Haaf Elevated levels of rad51 recombination protein in tumor cells Cancer Res 62 2002 219 225
21. T. Yanagisawa, M. Urade, Y. Yamamoto, and J. Furuyama Increased expression of human DNA repair genes, XRCC1, XRCC3 and RAD51, in radioresistant human KB carcinoma cell line N10 Oral Oncol 34 1998 524 528
22. S. Vispe, C. Cazaux, C. Lesca, and M. Defais Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation Nucl Acids Res 26 1998 2859 2864
23. H. Maacke, S. Opitz, K. Jost, W. Hamdorf, W. Henning, and S. Kruger Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer Int J Cancer 88 2000 907 913
24. H. Maacke, K. Jost, S. Opitz, S. Miska, Y. Yuan, and L. Hasselbach DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma Oncogene 19 2000 2791 2795
25. A. Slupianek, C. Schmutte, G. Tombline, M. Nieborowska-Skorska, G. Hoser, and M.O. Nowicki BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance Mol Cell 8 2001 795 806
26. L.H. Thompson, and D. Schild Homologous recombinational repair of DNA ensures mammalian chromosome stability Mutat Res 477 2001 131 153
27. W. Henning, and H.W. Sturzbecher Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance Toxicology 193 2003 91 109
28. Z.M. Wang, Z.P. Chen, Z.Y. Xu, G. Christodoulopoulos, V. Bello, and G. Mohr In vitro evidence for homologous recombinational repair in resistance to melphalan J Natl Cancer Inst 93 2001 1473 1478
29. J. Essers, R.W. Hendriks, S.M. Swagemakers, C. Troelstra, J. De Wit, and D. Bootsma Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination Cell 89 1997 195 204
30. X. Cui, M. Brenneman, J. Meyne, M. Oshimura, E.H. Goodwin, and D.J. Chen The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells Mutat Res 434 1999 75 88
31. H. Wang, Z.C. Zeng, T.A. Bui, S.J. DiBiase, W. Qin, and F. Xia Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2 Cancer Res 61 2001 270 277
32. A. Bhattacharyya, U.S. Ear, B.H. Koller, R.R. Weichselbaum, and D.K. Bishop The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J Biol Chem 275 2000 23899 23903
33. J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.M. Gilmore, M. Carty, and P.G. Johnston BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 63 2003 6221 6228
34. F.M. Wachters, J.W.G. Van Putten, H. Kramer, Z. Erjavec, P. Eppinga, and J.H. Strijbos First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial Br J Cancer 89 2003 1192 1197
35. M. Dabholkar, F. Bostick-Bruton, C. Weber, V.A. Bohr, C. Egwuagu, and E. Reed ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J Natl Cancer Inst 84 1992 1512 1517
36. A. Kreil, J. Bauer, and W. Scheithauer In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma Acta Med Austriaca 26 1999 93 100
37. J.W.G. Van Putten, P. Eppinga, Z. Erjavec, G.P.J. De Leede, J. Nabers, and J.B. Smeets Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study Br J Cancer 82 2000 806 811
38. R.D. Anderson, N.A. Berger International Commission for Protection Against Environmental Mutagens and Carcinogens Mutagenicity and carcinogenicity of topoisomerase-interactive agents Mutat Res 309 1994 109 142
39. T. Haaf, E. Raderschall, G. Reddy, D.C. Ward, C.M. Radding, and E.I. Golub Sequestration of mammalian Rad51-recombination protein into micronuclei J Cell Biol 144 1999 11 20